Ana Ferrigno Guajardo, MD, discusses lingering questions following the results of a study on taxane chemotherapy interventions in patients with breast cancer during pregnancy.
Experts introduce the antibody-drug conjugates (ADCs) trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd) and discuss clinical trial findings and potential use in special patient populations, such as those with brain metastases.